UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

Morgan Stanley analyst Sarita Kapila assumed coverage of UCB (UCBJF) with an Equal Weight rating and EUR 200 price target The firm says the ...

Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

After hours: February 13 at 5:41:33 PM EST ...

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...

NORTHFIELD, Minn., Feb. 13, 2025 /PRNewswire/ -- Aurora Pharmaceutical is pleased to announce the availability of EquiCoxib, the FDA-approved generic equivalent of Equioxx ® (firocoxib), a non ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.